| All patients n = 124 | Bronchiectasis n = 13 | Non-bronchiectasis n = 111 | p value |
---|---|---|---|---|
Median time of follow-up, months (IQR) | 59 (21–99) | 46 (15–89) | 60 (21–100) | 0.504 |
Death, n (%) | 35 (28.2%) | 5 (38.5%) | 30 (27.0%) | 0.515 |
Cause of death | ||||
 Infection | 10 (26.6%) | 3 (60.0%) | 7 (23.3%) | 0.642 |
 CLAD | 9 (25.7%) | 2 (40.0%) | 7 (23.3%) |  |
 Primary graft dysfunction | 6 (17.1%) | 0 (0.0%) | 6 (20.0%) |  |
 Cardiovascular complications | 3 (8.6%) | 0 (0.0%) | 3 (10.0%) |  |
 Gastrointestinal complications | 2 (5.7%) | 0 (0.0%) | 2 (6.7%) |  |
 Malignancy | 2 (5.7%) | 0 (0.0%) | 2 (6.7%) |  |
 Technical complications | 1 (2.9%) | 0 (0.0%) | 1 (3.3%) |  |
 Other | 2 (5.7%) | 0 (0.0%) | 2 (6.7%) |  |
Median time to death, months (IQR) | 15 (1–58) | 25 (3–85) | 14 (1–58) | 0.775 |
CLAD, n (%) | 35 (28.2%) | 4 (30.8%) | 31 (27.9%) | 0.999 |
Median time to CLAD development, months (IQR) | 60 (24–60) | 24 (12–45) | 72 (36–96) | 0.036 |
Pseudomonas colonization, n (%) | 29 (23.4%) | 8 (61.5%) | 21 (18.9%) | 0.002 |
Median time to first isolation of Pseudomonas, months (IQR) | 24 (6–78) | 30 (4–93) | 24 (9–66) | 0.857 |